We did observe a significantly lower median proportion of the apolipoprotein B mRNA editing catalytic polypeptide-like–related signature SBS2 in breast cancers, SBS6 in colorectal carcinoma, and SBS5 in HCC in the OM cohort compared with MSK. The gene discussed is APOB; the disease is breast cancer.